Skip to content

Boris B. Quednow

45 papers in the library · 1,535 citations · publishing 2004-2026

Papers

Sort Most recent Most cited

Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis

Neuropsychopharmacology March 3, 2021 Nora Penzel, Linda A. Antonucci, Linda T. Betz et al. 18 citations

Cannabis use during adolescence is associated with an increased risk of developing psychosis. According to a current hypothesis, this results from detrimental effects of early cannabis use on brain maturation during this vulnerable period. However, studies investigating the interaction between early cannabis use and brain structural alterations hitherto reported inconclusive findings. We...

DOI: 10.1038/s41386-021-00977-9 (opens in new tab) Full text (opens in new tab) Psychosis Schizophrenia object-oriented programming Confounding Age of onset +4

Serotonin and schizophrenia

Handbook of Behavioral Neuroscience 2020 Boris B. Quednow, Mark A. Geyer, Adam L. Halberstadt

Although the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is involved in the origin and progress of schizophrenia has considerably changed over the past decades. Therefore, the present work will give an overview about the development and the current...

Gamma‐hydroxybutyrate increases brain resting‐state functional connectivity of the salience network and dorsal nexus in humans

Neuroimage June 1, 2018 Oliver G. Bosch, F. Esposito, Dario Dornbierer et al.

&NA; According to the triple network hypothesis the brain is equipped with three core neurocognitive networks: the default mode (DMN), the salience (SN), and the central executive (CEN) network. Moreover, the so called dorsal nexus, has met growing interest as it is a hub region connecting these three networks. Assessment of resting‐state functional connectivity (rsFC) of these networks enables...

Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy").

The International Journal of Neuropsychopharmacology April 1, 2018 Michael D. Wunderli, Matthias Vonmoos, Lorena Treichler et al.

The empathogen 3,4-methylenedioxymethamphetamine (MDMA) is the prototypical prosocial club drug inducing emotional openness to others. It has recently been shown that acutely applied 3,4-MDMA in fact enhances emotional empathy and prosocial behavior, while it simultaneously decreases cognitive empathy. However, the long-term effects of 3,4-MDMA use on socio-cognitive functions and social...

Discrete memory impairments in largely pure chronic users of MDMA.

European Neuropsychopharmacology October 1, 2017 Michael D. Wunderli, Matthias Vonmoos, Marina Fürst et al. 37 citations

Chronic use of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") has repeatedly been associated with deficits in working memory, declarative memory, and executive functions. However, previous findings regarding working memory and executive function are inconclusive yet, as in most studies concomitant stimulant use, which is known to affect these functions, was not adequately controlled for....

Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs

Frontiers in Psychiatry August 18, 2017 Zurina Hassan, Oliver G. Bosch, Darshan Singh et al. 62 citations

A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects. These drugs change the mental state and/or the behavioral performance of an individual and can be instrumentalized for various purposes. After the emergence of a novel psychoactive substance (NPS) and a period of experimental...

DOI: 10.3389/fpsyt.2017.00152 (opens in new tab) Psychotropic drugs Mind-altering substances Novel compounds Medical benefits +6

MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘Ecstasy’ users

Neuroscience & Biobehavioral Reviews August 8, 2017 Carl Alexander Roberts, Boris B. Quednow, Catharine Montgomery et al. 25 citations

MDMA/Ecstasy has had a resurgence in popularity, with recent supplies comprising higher strength MDMA, potentially leading to increased drug-related harm. Neurocognitive problems have been widely reported in ecstasy users, equally some studies report null findings, and it remains unclear which factors underlie the development of neurocognitive impairments. This review covers the empirical...

Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers

Psychopharmacology July 1, 2017 Robin Rotz, Michael Kometer, Dario Dornbierer et al. 19 citations

Rationale Gamma-hydroxybutyrate (GHB) is a putative neurotransmitter, a drug of abuse, an anesthetic agent, and a treatment for neuropsychiatric disorders. In previous electroencephalography (EEG) studies, GHB was shown to induce an electrophysiological pattern of “paradoxical EEG-behavioral dissociation” characterized by increased delta and theta oscillations usually associated with sleep...

DOI: 10.1007/s00213-017-4603-z (opens in new tab) Full text (opens in new tab) Sodium oxybate Gamma hydroxybutyric acid Source localization Lagged phase synchronization +3

Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans

European Neuropsychopharmacology March 8, 2017 Oliver G. Bosch, Michael M. Havranek, A Baumberger et al. 22 citations

-receptor agonist currently used as treatment for narcolepsy but also as a drug of abuse. Non-medical GHB users have repeatedly reported prosexual effects including libido-enhancement and lowering of attractiveness standards for partner selection. Here, we examined the putative prosexual effects of oral GHB in healthy males in two experiments both employing randomized, placebo-controlled,...

DOI: 10.1016/j.euroneuro.2017.02.006 (opens in new tab) Sexual arousal Nucleus accumbens Gamma hydroxybutyrate Ventrolateral prefrontal cortex +6

Pharmacokinetics and pharmacodynamics of γ‐hydroxybutyrate in healthy subjects

British Journal of Clinical Pharmacology December 11, 2015 Matthias E. Liechti, Boris B. Quednow, Evangelia Liakoni et al. 57 citations

AIMS: γ-Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol withdrawal and as a recreational substance. Nevertheless, there are limited data on the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of GHB in humans. We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship of GHB in humans. METHODS: Two oral doses of GHB (25...

DOI: 10.1111/bcp.12863 (opens in new tab) Pharmacokinetics Sedation Pharmacodynamics Stimulant +7

Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone

Psychoneuroendocrinology July 17, 2015 Oliver G. Bosch, Christoph Eisenegger, Jürg Gertsch et al. 42 citations

Gamma-hydroxybutyrate (GHB) is a GHB-/GABAB-receptor agonist. Reports from GHB abusers indicate euphoric, prosocial, and empathogenic effects of the drug. We measured the effects of GHB on mood, prosocial behavior, social and non-social cognition and assessed potential underlying neuroendocrine mechanisms. GHB (20mg/kg) was tested in 16 healthy males, using a randomized, placebo-controlled,...

DOI: 10.1016/j.psyneuen.2015.07.167 (opens in new tab) Prosocial behavior Adrenocorticotropic hormone Testosterone patch Mood +8

Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships

European Neuropsychopharmacology December 4, 2014 Yasmin Schmid, Cédric M. Hysek, Katrin H. Preller et al. 39 citations

Methylphenidate mainly enhances dopamine neurotransmission whereas 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") mainly enhances serotonin neurotransmission. However, both drugs also induce a weaker increase of cerebral noradrenaline exerting sympathomimetic properties. Dopaminergic psychostimulants are reported to increase sexual drive, while serotonergic drugs typically impair sexual...

Differential effects of MDMA and methylphenidate on social cognition

Journal of Psychopharmacology July 22, 2014 Yasmin Schmid, Cédric M. Hysek, Linda D. Simmler et al. 154 citations

Social cognition is important in everyday-life social interactions. The social cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and methylphenidate (both used for neuroenhancement and as party drugs) are largely unknown. We investigated the acute effects of MDMA (75 mg), methylphenidate (40 mg) and placebo using the Facial Emotion Recognition Task, Multifaceted Empathy...

MDMA enhances emotional empathy and prosocial behavior

Social Cognitive and Affective Neuroscience October 4, 2013 Cédric M. Hysek, Yasmin Schmid, Linda D. Simmler et al. 356 citations

3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') releases serotonin and norepinephrine. MDMA is reported to produce empathogenic and prosocial feelings. It is unknown whether MDMA in fact alters empathic concern and prosocial behavior. We investigated the acute effects of MDMA using the Multifaceted Empathy Test (MET), dynamic Face Emotion Recognition Task (FERT) and Social Value Orientation...

Verbal Memory Deficits Are Correlated with Prefrontal Hypometabolism in 18FDG PET of Recreational MDMA Users

PLoS One April 9, 2013 Oliver G. Bosch, Michael Wagner, Frank Jessen et al. 34 citations

Verbal learning and recall deficits of recreational MDMA users are correlated with glucose hypometabolism in prefrontal and parietal cortex, while word recognition was additionally correlated with mediotemporal hypometabolism. We conclude that memory deficits of MDMA users arise from combined fronto-parieto-mediotemporal dysfunction.

DOI: 10.1371/journal.pone.0061234 (opens in new tab) MDMA Ecstasy Hippocampus Dorsolateral prefrontal cortex +2

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Neuropsychopharmacology September 28, 2011 Boris B. Quednow, Michael Kometer, Mark A. Geyer et al. 241 citations

The serotonin-2A receptor (5-HT(2A)R) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients. The hallucinogen psilocybin disrupts automatic forms of sensorimotor gating and response inhibition in humans, but it is unclear so far whether the 5-HT(2A)R or 5-HT(1A)R agonist properties of its bioactive...

The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval

Neuropsychopharmacology February 14, 2007 Franz X. Vollenweider, Philipp A Csomor, Bernhard Knappe et al. 194 citations

Schizophrenia patients exhibit impairments in prepulse inhibition (PPI) of the startle response. Hallucinogenic 5-HT(2A) receptor agonists are used for animal models of schizophrenia because they mimic some symptoms of schizophrenia in humans and induce PPI deficits in animals. Nevertheless, one report indicates that the 5-HT(2A) receptor agonist psilocybin increases PPI in healthy humans....

DOI: 10.1038/sj.npp.1301324 (opens in new tab) Full text (opens in new tab) Psilocybin Prepulse inhibition Hallucinogen Interstimulus interval +7

Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction

Journal of Psychopharmacology March 30, 2006 Boris B. Quednow, Frank Jessen, Kai‐uwe Kühn et al. 105 citations

Chronic administration of the common club drug 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and non-human primates, and evidence suggests that recreational MDMA consumption may also affect the human serotonergic system. Moreover, it was consistently shown that abstinent MDMA users...

Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (“Ecstasy”)

Psychopharmacology January 20, 2006 Boris B. Quednow, K. Kühn, C. Hoppe et al.

RationaleIn animal studies, the common club drug 3,4-methylendioxymethamphetamine (MDMA, “Ecstasy”) consistently caused a prolonged loss of presynaptic serotonergic neurons, and evidence suggests that MDMA consumption may also affect the human serotonergic system. Serotonin (5-HT) has been implicated in the regulation of impulsivity and such executive functions as decision-making cognition. In...

Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls.

Neuropsychopharmacology May 2004 Boris B. Quednow, Kai‐uwe Kühn, Klaus Hoenig et al.

Chronic administration of 3,4-methylenedioxymethamphetamine (MDMA) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and nonhuman primates. Despite the broad database concerning the selective serotonergic neurotoxicity of recreational MDMA consumption by humans, controversy still exists with respect to the question of whether the...